Research programme: recombinant fusion proteins - Trojantech
Alternative Names: Antennapedia Mastermind; Antennapedia Numb; Antennapedia p21; Antennapedia p53; ANTP Notch; ANTP p21; ANTP p53; NTP Mastermind; TR 1; TR 2; TR 3; TR 4Latest Information Update: 04 Nov 2017
At a glance
- Originator Trojantec
- Class Antineoplastics; Peptides; Recombinant fusion proteins; Transcription factors; Tumour suppressor proteins
- Mechanism of Action Apoptosis stimulants; Cell cycle stimulants; Transcription factor stimulants; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 14 Apr 2016 Pharmacodynamic data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
- 16 Apr 2015 TR 1 licensed to Sellas Life Sciences Group